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Objective: Epstein–Barr virus (EBV) infection is an established risk factor for B-cell lymphomas in Human
Immunodeﬁciency virus (HIV)-1 infected patients. A disturbed EBV-host relationship is seen in patient
groups with a high risk for EBV-associated lymphomas. We have analysed this relationship by measuring
EBV-DNA in the blood of HIV-1 carriers.
Method: EBV-DNA load in B-cells was monitored by PCR in non- or insufﬁciently antiretroviral treated
and rgp160-vaccinated HIV-patients.
Results: Both asymptomatic HIV-infected and AIDS-patients showed a 25–40-fold increase in the number
of B cell associated EBV-DNAcopies compared to healthy controls. Patients included in a vaccine trialwith
recombinant HIV gp160 showed a 5-fold increase of EBV load compared to non-immunised patients andaccination
HI
a 50-fold increase compared to healthy controls. There was no difference whether they received vaccine
or “placebo”. Vaccinated patients with a history of symptomatic primary HIV-1 infection (PHI) had a
280-fold increase in median EBV load compared to healthy controls, thus suggesting a synergistic effect
between the vaccination and PHI, which hypothetically could affect lymphoma risk.
Conclusions: We recommend analysis of EBV-load and long term follow up of lymphoma risk in all
therapeutic HIV-1 vaccination trials.. Introduction
Epstein–Barr virus (EBV) is present in more than 90% of all
uman adults and establishes lifelong latency in B cells in the
uman host after primary infection [1]. When immune con-
rol is suppressed the virus can be reactivated as for example
n transplanted individuals [2]. Latent EBV infection in B lym-
hocytes is likely to be a risk factor for B-cell lymphomas in
onditions of combined antigen stimulation and immunosup-
ression, e.g. in holoendemic malaria, after transplantation, and
Abbreviations: EBV, Epstein–Barr virus; HIV, Human Immunodeﬁciency virus;
HI, history of symptomatic primary HIV-infection.
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in human immunodeﬁciency virus (HIV)-1 induced immunodeﬁ-
ciency [3].
Before the introduction of anti-retroviral therapy, the risk of
developing B-cell lymphomas in HIV-1 seropositive patients was
several thousand fold higher than in HIV-1 sero-negative persons
of the same age group [4]. Thirty–forty percent of the periph-
eral lymphomas and close to 100% of the primary central nervous
system (CNS) lymphomas were EBV-positive [5]. In post-mortem
examinations, 19% of AIDS-patients were diagnosed to have non
Hodgkin lymphoma [6]. The lymphoma risk, especially the pri-
mary CNS lymphomas, has signiﬁcantly decreased, in the era
of combination anti-retroviral therapy (cART) [7]. An over-risk
for non-Hodgkin lymphomas (NHL) still remains in HIV-infected
patients [8,9].
Defective T-cell immunity in patients has previously been
shown to result in an abnormally high number of EBV-infected B
cells in blood, e.g. in chronic active EBV infection, post-transplant
patients and in HIV-infected patients [10,11].
Vaccination including adjuvant may affect the EBV-host bal-
ance, especially in immunocompromised individuals, e.g. those
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tion was observed. There was no signiﬁcant statistical difference
as regards age, sex, and antiretroviral treatment when comparing
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ith HIV-1 infection as it affects HIV-1-, EBV-, CMV- and/or HCV-
peciﬁc CD4 T-cells [12,13]. This vaccination effect on speciﬁc CD4
-cells might in turn also affect the B-cell compartment [14,15]. A
istory of symptomatic primary HIV-1 infection (PHI) is also known
o affect the composition of the B-lymphocyte pool [16].
In  this paper we analyse subgroups of non- or insufﬁciently
ntiretroviral treated HIV-infected patients and their EBV-host
elation measured by EBV genome load. Vaccination with recom-
inant HIV-1 gp160 (rgp160)/adjuvant and symptomatic primary
IV-infection (PHI) both affects B-cell function. We  show an
ncreased EBV-load in blood B-cells after therapeutic vaccination
nd a further enhancement of EBV-DNA in patients with a history
f PHI.
. Material and methods
.1.  Patients and controls
Sixty  HIV-1 positive patients from the outpatient clinic at Hud-
inge hospital and/or South Hospital, Stockholm, including 42
articipants in vaccine trials were randomly selected for this study
Tables 1 and 2). After informed consent 20 mL  of blood was
ollected. HIV-1 negative controls (not matched for age, sex or
isk group) were selected among healthy laboratory personnel.
ermission for the study was obtained from the regional Eth-
cal Committee at the Karolinska Institute (#51/97). Of the 42
mmunised individuals, 32 participated for two years in a dou-
le blind placebo controlled phase III vaccine trial with r160
rgp160)/”placebo” [17]. Both in the rgp160 vaccine and placebo
rm alum was included as adjuvant. In this early vaccine trial
atients received at least eight vaccinations with alum/rgp160 at
egular intervals for 21 months. Placebo was given according to the
ame time schedules. The other 10 patients were during more than
hree years included in an on-going open phase II clinical study with
he same vaccine. These patients got 12–16 vaccinations during
hree years.
The  patients were treated during the pre-HAART/cART era with
ne or two nucleoside analogues or foscarnet. We  designate this
reatment regimen as insufﬁcient antiretroviral therapy, as indi-
ated both by CD4 counts and breakthroughs of HIV RNA levels.
Sex,  age, patient origin, route of transmission, CD4+ and CD8+
ell counts are summarised in Table 1.
Throat washes for EBV DNA analysis were collected at the same
ime as blood samples from 31 of the HIV-1 seropositive patients
ncluded in the rgp160 vaccine trials and from three HIV-1 seropos-
tive patients who were not included in any of the rgp160 vaccine
rials. The patients were asked to gargle for 30 s with 20 ml  of 0.9%
odium chloride.
able 1
ummary of patient characteristics.
Sex (M/F)a Median age (range) Geographic origina
(Eur/non-Eur)
Rou
tran
(HS
HIV-1 asymptomatic
7/1  38 7/1 6/2
HIV-1  symptomatic
10/0 42 8/2 9/1
HIV-1  vaccinated asymptomaticb
32/5 37 30/5 24/
HIV-1  vaccinated symptomatic
5/0  43 5/0 5/0
HIV-1  seronegative
5/5 30 9/1 – 
T = not tested.
a M:  male; F: female; Eur: European; non-Eur: non-European; HS: homosexual; IV: Int
b Included in vaccine trial receiving rgp160 or placebo, alum.0 (2012) 6093– 6098
2.2. EBV serology
EBV  IgG antibody titers to EA and VCA was  determined in plasma
by conventional immunoﬂuoroscence applied to antigen positive
cells. IgG and IgM titers were determined against EBNA 1 with
peptide (p107) based ELISA.
2.2.1.  DNA preparation from saliva
The patients gargled with 10 mL  of RPMI medium for 1 min. The
throat wash was centrifuged at 2000 rpm (approximately 600 × g)
for 10 min, and then the supernatant was  frozen at −70 ◦C until
testing. Half mL of the sample was lysed in 0.5 mL  of PCR-lysate
buffer [18].
2.3.  EBV genome load
EBV  DNA analysis and statistics were performed as previously
reported by Friis et al. [18]. This method is as sensitive and gives
similar results as quantitative PCR (qPCR) [2]. In addition it pro-
vides results in all samples, while qPCR may  fail more often due to
inhibition and quenching.
One  hundred L of plasma were lysed in 100 L PCR-lysate
buffer. Plasma samples were tested for positive respectively nega-
tive reaction using the same PCR condition as for blood.
2.3.1.  Statistical considerations
Non-parametric Mann Whitney or Kruskal Wallis tests were
applied, using StatView II (Abacus Concepts Inc.). Multivariate
analysis was  also performed using Simca-P 8.0 (Umetrics AB) but
did not add anything to our interpretation based on univariate
analysis.
3. Results
HIV-1 infected patients included in the rgp160 vaccine tri-
als showed higher median EBV-DNA load, 2.4 copies per 1000 B
cells (n = 42) compared to non-vaccinated HIV-carriers, 0.49 per
1000 B cells (n = 18; p < 0.01, Fig. 1A). Although the patients were
recruited from two  slightly different vaccination trials (see Materi-
als and Methods), we  found no statistical difference in EBV-DNA
load between the two  groups. A considerable individual varia-immunised and non-immunised patients (Table 1). However, in the
rgp160 study group higher CD4+ cell counts were detected, which is
most likely a result of the selection criteria for the vaccine trial. The
immunised group had a median value of 270 × 106 cells/L (n = 42)
te of
smission
/IV/Het)a
Median CD4 (range) Median CD8 (range)
/0 370 (120–810) 1200 (570–3840)
/0 25 (3–200) 480 (70–900)
2/11 290 (7–580) 930 (250–2590)
/0 70 (10–360) 680 (340–930)
NT NT
ravenous drug abuse, Het: heterosexual
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Table 2
Patient data.
No EBV genome loada CD4b CD8b Active vaccine
or  Alumc
Antiviral
treatment
Documented
primary infection
History >10 years of
HIV  infection
Other
HIV asymptomatic
1 0.13 230 1890 no AZT
2 0.19 340 1540 no ACVd(2 days)
3 0.89 330 570 no - +
4 0.19  510 1700 no − +
5  0.031 120 880 no −
6 0.29 610 770 no AZT,  DDI +
7  2.0 390 830 no −
8 0.43 810 3840 no −
HIV symptomatic
1 1.2 30 520 no AZT
2  2.4 200 760 no AZT HLPg
3 0.027 3 150 no −
4  0.49 4 70 no − HLP
5 0.53  20 580 no −
6 6.7 30 350 no AZT HLP
7  2.7 10 440 no − HLP
8  0.75 9 640 no ACV, DDI
9 2.0 40 410 no AZT, DDI
10 0.17 110 900 no −
HIV vaccinated asymptomatice
1 0.36 270 1050 A Foscavir
2 53 170 1510 vaccine − Lymphoma
3  3.3 360 1900 A − +
4  0.99 240 1070 vaccine AZT
5 0.29 360 910 vaccine −
6  400 320 2590 vaccine − +
7  4.6 120 510 vaccine ACV
8 8,8 270 1100 A ACV +
9 11 210 650 A DDC, ACV +
10 4.0 220 1190 A − +
11  63 290 1080 A −
12 0.080 270 1120 vaccine − +
13 0.090 200 1100 vaccine − +
14 2.1 170 640 A AZT +
15 5.3 480 1030 vaccine − +
16 0.11 430 1680 A − +
17 0.43  440 1900 vaccine − +
18 2.2  180 1460 vaccine AZT, DDI
19 0.043 230 870 A −
20 2.4 100 380 vaccine − +
21 1.2 240 580 vaccine −
22 0.42 510 1380 A −
23 1.2 360 800 vaccine −
24 3.2 560 800 A −
25 7.8 580 340 A −
26 23 490 790 A − +
27 5.6 410 730 A −
28 0.25 370 610 vaccinef −
29 3.6 190 670 vaccinef −
30 4.2 470 500 vaccinef −
31 90 310 1050 vaccinef − +
32 2.4 90 290 vaccinef AZT, DDI
33 0.49 370 1230 vaccinef − +
34  0.04 7 250 vaccinef AZT
35 34 160 1540 vaccinef AZT, DDI
36 2.0 440 930 vaccinef −
37 3.0 340 810 vaccinef −
HIV vaccinated symptomatic
1  2.3 360 680 vaccine − HLP
2  80 110 520 A DDI + Kaposis sarcoma,
epithelial cancer
3  0.17 70 740 A Foscavir
4 2.0 10 340 vaccine AZT HLP
5  1.2 40 930 vaccine − Kaposis sarcoma,
HLP
+ = history of symptomatic primary infection (PHI), − = no antiviral drug,
a Number of EBV genomes per 103 B-cells.
b Number of 106 cells per liter of blood.
c Recombinant active vaccine (vaccine), Alum (A), or no vaccine (no).
d Acyclovir.
e Includes placebo.
f Phase II, open rgp160 study.
g Hairy lekoplakia.
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Fig. 1. Boxplot representing median EBV values and distribution of the data of the
main patient groups compared in this study.
(A) HIV-l negative individuals, HIV-1 positive non- vaccinated individuals, and HIV-
l positive vaccinated individuals. (B) Vaccinated individuals receiving recombinant
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ap160  vaccine, vaccinated individuals receiving “placebo” adjuvant alone (Alum),
atients with documented symptoms upon HIV-1 primary infection (PHI), and
atients who  reported no PHI symptoms.
s compared to a median of 120 × 106 cells/L (n = 18) in the HIV-
 positive patients not included in the vaccine trial. We  observed
o signiﬁcant correlation between the CD4+ cell counts and the
BV load, although there was a tendency to inverted correlation
etween these variables that patients with a high EBV load had
ow CD4+ cell counts, and patients with a low EBV load had a high
D4+ cell count.
The  highest EBV values were exclusively found in the immu-
ised group, while low values could be seen both in immunised
nd non-immunised patients. In the non-immunised HIV-1 car-
iers, the asymptomatic patients had a median EBV load of 0.19
opies/1000 B-cells (n = 8) while patients with AIDS-diagnosis had
.98 copies/1000 B-cells (n = 10).
Notably,  patients who received adjuvant alone “placebo” (i.e.
lum) demonstrated an even higher EBV load (median 3.7 copies,0 (2012) 6093– 6098
n  = 16) than those who received rgp160 (also with alum; median
2.1 copies, n = 26; Fig. 1B).
In  general HIV-infected patients showed a higher EBV-DNA load
in their B-lymphocytes than controls. In the control group the
median EBV load was 0.049 per 1000 B cells (n = 10, Fig. 1A), while
the median value for all the HIV-l infected patients was forty times
higher, 2.0 per 1000 B cells (n = 60), a highly signiﬁcant differ-
ence (p < 0.0001). Sex, age, origin of the individuals, and insufﬁcient
antiretroviral treatment did not affect the EBV load. One patient had
a conﬁrmed diagnosis of lymphoma at the time of blood sampling.
This patient’s EBV load was 53 copies per 1.000 B cells.
The  inter-individual variation was large between HIV-1-
patients, ranging over 10,000-fold (Fig. 1A), from 0.027 to 400 EBV
copies per 1000 B cells. Forty percent (24/60) of the HIV-1 positive
individuals had the same range of EBV load as the controls.
The  difference in EBV load between symptomatic and asymp-
tomatic groups of HIV-1 patients was  relatively small, however a
tendency to higher load in the asymptomatic group was  noted [2.0
copies (n = 45) vs. 1.2 copies per 1000 B cells (n = 15), respectively].
The asymptomatic groups also showed a higher CD4 cell count.
This paradoxical ﬁnding may  be explained by vaccine effects, which
will be discussed later. The data from all the patient subgroups are
summarised in Table 3.
Immunised patients with a history of symptomatic primary HIV-
infection (PHI) had a median value of 14 copies per 1000 B cells
(n = 8), while the immunised individuals with no such history had
a signiﬁcantly lower median value of 2.1 copies per 1000 B cells
(n = 34, p < 0.05; Fig. 1B).
For patients in the vaccine trials with an asymptomatic HIV-1
infection lasting for longer than ten years, EBV load was some-
what lower (median 1.5 copies, n = 8) in comparison to individuals
with an asymptomatic infection lasting for a shorter period of time
(median 2.4 copies; n = 34). No statistically signiﬁcant differences
were found.
Antibody titers to EBV-antigens were determined in all patients
included in the vaccine trials, at the time of sampling for EBV-
DNA-load. Nine patients had IgG anti-EA titers >1:80, ten anti-VCA
titers >1:640 and three had elevated anti-p107 (EBNA 1)-titers in an
ELISA-test. Although this did not correlate to EBV-DNA load, HIV-
1 RNA levels or type of vaccine, the ﬁve patients with the highest
levels of EBV DNA-load also had higher antibody titers.
Thirty-three patients were also tested for EBV-DNA in blood
plasma. No EBV-DNA was detected in any of these samples. All of
the saliva samples (throat washes) from HIV-1 infected patients
were EBV-DNA PCR positive, but there was  only a four-fold vari-
ation between the patients tested, and no co-variation with EBV
DNA-load in B-lymphocytes (data not shown).
4. Discussion
Although HIV-1 infected patients seem to have signiﬁcantly
higher EBV load than controls, there is a stepwise increase from
the time of HIV-1 infection to AIDS [19]. During the last decade
the pathoimmunologic aspects on HIV-infection emphasise the B-
cell involvement in addition to the T-cell deﬁciency. Polyclonal
B-cell activation is a well-known consequence of HIV-infection,
including hypergammaglobulinemia and increased production of
autoantibodies [13,20]. Furthermore, the B-cell function in HIV-
infected patients can be impaired as a result of exhaustion due to
chronic persistent infection and apoptosis. Resting memory B-cells
are particularly vulnerable in favour of activated B-cells, short lived
plasmablasts and exhausted memory B-cells [13]. Immature, tran-
sitional positive B-cells undergo a development to CD21+ and later
CD20 + CD19- B-cells [21], in analogy with PTLD in post-transplant
patients [22]. As a result, the B-cells show a decreased ability to
A.M.C. Friis et al. / Vaccine 3
Table 3
Averages of EBV DNA load in blood B-lymphocytes divided according to different
patient  groups.
No of pat EBV load per
1000  B cells
Immunised 42 2.4**
Non-immunised 18 0.49**
Immunised
Asymptomatic 37 2.4
Symptomatic  (AIDS) 5 2.0
Placebo 16 3.7
Vaccine 26 2.1
With  PHI 8 14*
Without PHI 34 2.1*
Long term asymptomatic 8 1.5
<10  years asymptomatic 34 2.4
Non-immunised
Asymptomatic  8 0.19
Symptomatic  (AIDS) 10  0.98
HIV-1  seronegative controls 10 0.049***
HIV-1 seropositive 60 2.0***
HIV-1 seropositive
Asymptomatic 45 2.0***
Symptomatic (AIDS) 15 1.2***
*** = p < 0.001
**
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* = p < 0.05
eact to speciﬁc antigens, and this speciﬁc memory B-cell loss is
ot reversed by antiretroviral therapy [23].
Earlier publications suggest that vaccination by itself might lead
o a similar polyclonal B-cell activation [24,25]. Thus, any vacci-
ation might have a synergistic effect with the HIV-infection on
he B-cell homeostasis. Alum, as a vaccine adjuvant, has also been
inked to the development of cutaneous pseudolymphoma of B-cell
rigin probably via the induction of a Th2 response [26].
Vaccination of HIV-patients with tetanus or pneumococcal
ntigen as well as bacteriophage immunisation, have caused an
ncrease of the HIV-1 RNA levels [27–29]. However, the effect
f single as well as repeated vaccination on EBV load in healthy
ndividuals is unknown. To the best of our knowledge, no gen-
ral vaccination program exists where individuals are exposed to
accine, and thereby alum, as frequently as in therapeutic HIV-1
accination trials, as in our study (4–6 administration/year).
The inter-individual variation between the patients in our study
s considerable: the lowest quartile of EBV load in HIV-1 infected
ncluding AIDS-patients show similar values compared to the con-
rols. It has previously been shown in homosexual male patients
hat the relationship between individual EBV load values (“set
oints”) was maintained after HIV-1 seroconversion and also after
nitiation of antiretroviral treatment [30]. The EBV load in our study
oes not correlate well to the T-cell status of the patients, and there-
ore additional factors affecting the EBV load must be considered.
One  such concomitant factor seems to be the therapeutic vacci-
ation itself. In vaccinated patients there was a surprisingly similar
nﬂuence of the vaccination in those who received only the adjuvant
alum) and those who got the adjuvant with the recombinant pro-
ein. This phenomenon has not been observed in non-vaccinated
HI patients. A history of PHI among the patients further signiﬁ-
antly affected the EBV-host relationship, which was not observed
n non-vaccinated PHI patients [31].
Although we followed several of the vaccinated patients for 2–3
ears, we cannot make any conclusion concerning the persistent
ffect of immunisation on EBV DNA load. All analysed patients were
ntroduced on cART soon after ending the vaccine trials. The intro-
uction of cART affects the EBV host balance via the restoration of
he CD4+ positive cells. This is most likely a strong confounding
actor on the effect of immunisation on the EBV DNA load.0 (2012) 6093– 6098 6097
The immune stimulation caused by rgp160/alum may affect EBV
in two  ways. It may  be either through inﬂuence on EBV replication
resulting in infection of more B cells, or EBV infected B lympho-
cytes may  be stimulated to proliferate through the activation of
helper T-cells as a result of a Th2 enhancement by the vaccine. It
has been shown that gp160 HIV-vaccination up-regulates immune
activation T-cell markers, such as MHC  class II and CD38 helper T-
cells [32]. In an experimental prophylactic vaccination with gp120
in mice, the Th2-arm was  activated [33]. The effects of therapeu-
tic vaccination on T-cells might generate B-cell activation through
non-speciﬁc immune stimulation in HIV infected individuals, as
also shown for patients with autoimmune disease [15,32].
Our  method detects B cell-associated EBV genome load. The
method does not distinguish whether an expansion of EBV load in
infected cells was caused by an increased copy-number or if it was
caused by an increased number of infected cells. Using the same PCR
method in a study of blood from healthy donors, we have shown
that the number of EBV genome copies vary between 1–5 copies
per B cell in different B-cell subsets [34]. It is not known if this is
also valid in HIV-1 infected patients.
EBV-DNA PCR is a useful tool for monitoring clinical course
of lymphoproliferative disease and for identifying patients at risk
for tumours [11,35]. Measurement of EBV genome levels is then
usually performed in extra-cellular plasma as cell free virus DNA
[35,36]. However, Stevens et al. [11] concluded that serum may
not be an optimal clinical specimen for EBV DNA load-monitoring
because it does not consider the presence of cell-associated virus,
and uncontrolled cell lysis may  give irreproducible results or over-
estimation of the DNA load. However, we could not detect any
EBV-DNA in plasma from our patients, which might reﬂect their
relatively intact immune status. EBV DNA is rarely if ever detected
in plasma from healthy individuals [37]. Cell-free virus DNA  is
probably only detected when released from dying cells in EBV
carrying tumours or when the EBV host balance is signiﬁcantly
disturbed. Free virus may  also be derived due to the replication
of virus in sites outside blood in hosts with relaxed control of
EBV-latency.
Monitoring of EBV load in B cells directly reﬂects viral load
in the cell population, which most likely contains precursors of
potential B-cell lymphomas. As mentioned above, HIV-1-patients
do show both quantitative and qualitative variability of the B lym-
phocytes [13,38]. To circumvent this problem we analysed the load
in CD19+ B cells. The chronic B-cell activation together with the loss
of EBV immunoregulatory control seems to play a major role in the
development of EBV-positive NHL in HIV-1 infected patients [39].
Excessive expansion of EBV-infected B-cells together with a risk
for chromosome translocations conferring a malignant phenotype
might explain the increased frequency of B-cell malignancies [8,40].
Our results must be considered in view of the well-documented
decrease of lymphomas paralleled with the reconstitution of
the immune system observed after the implementation of
cART.
5. Conclusions
The major conclusion from our results is the recommendation to
combine EBV-load analysis together with a long-term follow up of
lymphoma risk in all therapeutic HIV-vaccine trials with or without
combination anti-retroviral therapy.
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